1. Effect of administered human growth hormone on growth retardation in inflammatory bowel disease
- Author
-
A. M. Lawrence, Thomas D. McCaffery, Khosrow Nasr, and Joseph B. Kirsner
- Subjects
Secondary hypopituitarism ,Adult ,Male ,medicine.medical_specialty ,Time Factors ,Anabolism ,Adolescent ,Physiology ,Hypopituitarism ,Growth hormone ,Inflammatory bowel disease ,Crohn Disease ,Internal medicine ,medicine ,Methods ,Humans ,Growth Disorders ,Growth retardation ,business.industry ,Human growth hormone ,Hypogonadism ,Gastroenterology ,General Medicine ,Hepatology ,medicine.disease ,Long-Term Care ,Enteritis ,Endocrinology ,Growth Hormone ,business ,hormones, hormone substitutes, and hormone antagonists - Abstract
In a previous study of 22 severely growth-retarded children with inflammatory bowel disease (IBD), endocrinologic evaluation revealed hypogonadism and low growth hormone (HGH) levels. This was attributed to a secondary hypopituitarism. In order to assess this hypothesis, two individuals from this group and another similar child who was not so severely growth-retarded as to be included in the initial study were given HGH replacement in an acute trial and for a 6-month interval. No significant height increment could be attributed to the HGH administration although a definite anabolic response was present in each patient during the acute trial. It appears that the youngsters with IBD may have a relative end-organ resistance to the metabolic and growth-promoting effects of HGH and that their growth problems are not related to hypopituitarism.
- Published
- 1974